SteadyMed Provides Corporate Update and Reports Third

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
SteadyMed Provides Corporate Update and Reports Third Quarter 2016 Financial Results

SAN RAMON, Calif., Nov. 14, 2016 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq: STDY ), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today provided a corporate update and announced its financial results for the third quarter ended September 30, 2016.

2016 Corporate Update:    

  • In June, the Company held a pre-NDA meeting with FDA, confirming the requirements for the 2017 submission of a New Drug Application (NDA) for Trevyent®, the Company’s lead drug product candidate that combines SteadyMed’s proprietary, preservative free formulation of treprostinil and its patent protected PatchPump platform technology. Trevyent is in development for the treatment of Pulmonary Arterial Hypertension (PAH).  
  • In August , the Company closed the first tranche of a two-tranche private placement financing for up to $32 million of ordinary shares with warrants, with $21.3 million received at the initial closing and $10.7 million, without warrants, committed upon achievement of certain milestones by September 30, 2017. New investor OrbiMed led the financing, with participation from existing investors, including Federated Investors, Inc. and Deerfield Management. SteadyMed expects this financing will allow it to further develop Trevyent through submission of a NDA, scale up Trevyent commercial manufacturing capabilities and prepare for a late 2017 U.S. product launch with its own commercial infrastructure.  
  • The manufacture of the Registration Stability Lots (RSL’s) of Trevyent® was completed in August. The data to be generated from these RSL’s is expected to determine the shelf life of Trevyent upon commercial launch and the timing of completion supports the on time anticipated launch of Trevyent, in the U.S., in late 2017, subject to NDA submission in Q2 2017, priority review and approval by the U.S. Food and Drug Administration (FDA). The RSL’s were manufactured utilizing the final commercial supply chain infrastructure, in compliance with current Good Manufacturing Practice (cGMP) standards.  
  • In October, Senior Executives gave a poster presentation providing an overview of the development of Trevyent and of its PatchPump technology at the Parenteral Drug Association Conference in Huntington Beach, California.  The poster included newly disclosed data relating to SteadyMed’s RSL program and ongoing Development Stability Program for Trevyent. The data showed a high degree of uniformity for all batches produced in the RSL campaign, as well as through 18 months of storage in the stability program.  
  • The Company continues to progress its Inter Partes Review (IPR) challenge against U.S. Patent No. 8,497,393 (the '393 patent) owned by United Therapeutics. The patent relates to a product made by a process to generate prostacyclin derivatives, such as treprostinil, the active pharmaceutical ingredient used in United Therapeutics' Remodulin® and SteadyMed's lead drug candidate, Trevyent. Upon institution of the IPR, in April 2016, the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO) stated that PTAB has "reviewed SteadyMed’s evidence, arguments, and claim charts” and concluded that “for the foregoing reasons we determine that the information presented in the Petition establishes that there is a reasonable likelihood that SteadyMed would prevail in challenging claims 1–22 of the ’393 patent”. Claims 1-22 constitute all the claims of the ‘393 patent. SteadyMed believes the IPR is progressing favorably for the Company, and looks forward to the final oral hearing at PTAB on November 29, 2016 followed by a final decision on or around April 8, 2017.    
  • To coincide with November PAH awareness month, SteadyMed launched a new website, BePhenomenal.com, that is dedicated to educating and empowering people living with PAH so that they can live their healthiest and most PHenomenal lives. BePhenomenal.com will offer expert lifestyle information customized for people within the PH community.             

“During the third quarter, we achieved many significant steps in preparing for our NDA filing for Trevyent, including our financing and completion of the manufacture of our Trevyent Registration Stability Lots on our commercial manufacturing infrastructure,” said Jonathan Rigby, President and Chief Executive Officer of SteadyMed. “This enables us to maintain our timelines for potential launch of Trevyent, in the U.S., by the end of next year, if our NDA for Trevyent gains priority review and is approved. These are exciting times for SteadyMed and our commercial team has begun to develop the launch strategy and begun market preparations to prepare for a strong Trevyent market entry later next year.”

Third Quarter 2016 Financial Results Compared to Third Quarter 2015 Financial Results

SteadyMed recorded licensing revenues of $0.276 million for the third quarter of 2016, compared to $0.439 million of revenues in the third quarter of 2015. Licensing is the only source of revenue at this time as the company has not received regulatory approvals to sell Trevyent or any of other product candidate.

For the third quarter of 2016, the company reported a net loss of $10 million, or $0.57 per share, compared to a net loss $5.9 million, or $0.44 per share in the third quarter of 2015.  The loss per share for the third quarter of 2016 was calculated based on 17,646,450 weighted-average shares outstanding, versus 13,581,160 in the third quarter of 2015.

Total operating expenses for the third quarter of 2016 were $8 million, versus $6.3 million for the third quarter of 2015. The increase in total operating expenses was primarily attributable to an increase in research and development (R&D) expenses related to Trevyent, an increase in general and administrative (G&A) expenses primarily related to the costs of staffing and an increase in sales and marketing (S&M) primarily related to the ramping up of the pre-commercialization program for Trevyent.

R&D expenses for the third quarter of 2016 were $6 million, compared to $4.8 million for the Third Quarter of 2015.  The increase in R&D expenses was primarily due to an increase in subcontractors’ and material expenses related to the Trevyent development program.

G&A expenses for the Third Quarter of 2016 were $1.5 million, compared to $1.3 million for the Third Quarter of 2015. The increase in G&A expenses was primarily due to increases in stock-based compensation and other salary related costs. 

S&M expenses for the third quarter of 2016 were $0.4 million compared to $0.2 million during the third quarter of 2015. The increase in S&M was primarily due to an increase in consulting fees related to the ramping up of the pre-commercialization efforts for Trevyent.

Financial expenses, net, for the third quarter of 2016 amounted to $2.3 million compared to $0.06 million in financial income, net, during the third quarter of 2015 resulted primarily from issuance costs of shares and warrants in the third quarter of 2016 out of which $0.8 million was allocated to warrants and expensed and $1.5 million in expense from revaluation of the fair value of such warrants.

Cash and cash equivalents were $31.5 million as of September 30, 2016.

About SteadyMed

SteadyMed Ltd. is a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases with unmet parenteral delivery needs. The company's lead drug product candidate is Trevyent®, a development stage drug product that combines SteadyMed's PatchPump® technology with treprostinil, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension (PAH). SteadyMed intends to commercialize Trevyent in the U.S. and has signed an exclusive license and supply agreement with Cardiome Pharma Corp. for the commercialization of Trevyent in Europe, Canada and the Middle East. SteadyMed has offices in San Ramon, California and Rehovot, Israel. For additional information about SteadyMed please visit www.steadymed.com .

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements about the company's ability to advance its development-stage product candidates, including Trevyent, statements about the potential benefits of our development-stage product candidates and our PatchPump technology, statements about the potential outcome of Inter Partes Review of U.S. Patent No. 8,497,393, statements about the potential benefits of orphan drug designation, and statements about our ability to obtain and maintain regulatory approval of our development-stage product candidates. Forward-looking statements reflect the company's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause actual results to differ materially. Risks and uncertainties include, but are not limited to, the risk that Trevyent does not demonstrate clinical superiority to existing parenteral treprostinil products, that Trevyent is not approved for commercialization by the FDA, that Trevyent is not granted orphan drug exclusivity, and the risk that drug development involves a lengthy and expensive process with uncertain outcome. The risks, uncertainties and assumptions referred to above are discussed in detail in our reports filed with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q filed on November 14, 2016. The company does not undertake to publicly update or revise any forward-looking statements to reflect events or circumstances that may arise after the date hereof except as may be required by law.

   
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS  
U.S. dollars in thousands (except share data)  
   
    Three months ended September  30,   Nine months ended September  30,  
    2016   2015   2016   2015  
    Unaudited   Unaudited  
Revenues   $   276   $ 439     $   745   $ 439    
                   
Operating expenses:                  
Research and development   $   6,044   $   4,799     $   16,312   $   14,637    
Sales and marketing   435     216     1,258     723    
General and administrative   1,487     1,308     4,167     3,324    
                   
Total operating expenses   7,966     6,323     21,737     18,684    
                   
Total operating loss   7,690     5,884     20,992     18,245    
                   
Financial expenses (income), net   2,260     (58 )   2,177     (69 )  
                   
Loss before taxes on income   9,950     5,826     23,169     18,176    
                   
Taxes on income   56     115     268     246    
                   
Net loss   $   10,006   $   5,941     $   23,437   $   18,422    
Net loss per share:                  
Basic and diluted net loss per Ordinary Share   $   (0.57 )   $   (0.44 )   $   (1.57 )   $   (2.02 )  
Weighted-average number of Ordinary Shares used to compute basic and diluted net loss per share   17,646,450     13,581,160     14,949,237     9,586,245    
                           
CONSOLIDATED BALANCE SHEETS
U.S. dollars in thousands
             
      September 30,      December 31,
      2016      2015
      Unaudited      
             
Assets:          
           
Cash and cash equivalents   $ 31,504     $ 31,851  
                 
Other assets     3,966       3,379  
           
Total assets   $ 35,470     $ 35,230  
         
Liabilities and shareholders' equity:        
         
Current liabilities   $ 7,378     $ 5,840  
         
Non-current liabilities:        
Liability related to warrants     11,076       -  
Other liabilities     507       843  
                 
Shareholders' equity     16,509       28,547  
         
Total liabilities and shareholders' equity   $ 35,470     $ 35,230  

 

Contacts: Marylyn Rigby Senior Director, Investor Relations and Marketing 925-272-4999 mrigby@steadymed.com The Ruth Group David Burke (646) 536-7009 dburke@theruthgroup.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 159

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 147

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Loyalty Programs Cut $1500 Annually for Consumers

Updated Category News Views 16

Loyalty Programs: An Essential Tool for Households In a world where every dollar counts, retail loyalty programs have become more than just a marketing strategy—they're lifelines for American households scraping through each month. According to fresh research by the Retail Industry Leaders Association (RILA) and conducted by market research leader Circana, these...

Continue Reading
LONGi's Four Paths to Global Green Development

Updated Category News Views 177

LONGi's Vision: A Cleaner, Greener Future Amidst the buzz at COP31 in Antalya, LONGi is making waves with promises of a cleaner future. They're not just throwing around eco-friendly slogans—this company's laying down real pathways to tackle climate change, one solar panel at a time. Aiming for Industrial Transformation LONGi's got their sights set on shaking up...

Continue Reading
Older Adults Embrace Cosmetic Dentistry for Confidence

Updated Category News Views 17

Why the Shift to Cosmetic Dentistry Later in Life? Aging doesn't just wrinkle your skin; it affects your smile too. Dr. Joseph T. Sumrall and Dr. Gran Sumrall, the dental gurus of Warner Robins, Georgia, are laying out why more adults are jumping on the cosmetic dentistry bandwagon as they age. Spoiler: It ain't about getting a movie-star grin but something much deeper....

Continue Reading
Hermes AI: A New Era in Market Analysis?

Updated Category News Views 21

Revolution or Just Another App? In a world where stock market insights are as cryptic as hieroglyphs to the average Joe, here comes the Hermes AI Analyzer, breaking onto the scene and promising to translate Wall Street's complex lingo into plain, simple language. It's the brainchild of Turkish engineer Umut Tugrul, who has spent decades in the trenches of software...

Continue Reading
Baidu's Q3 2026: AI Explodes Amid Marketing Slump

Updated Category News Views 35

Baidu Looks to AI as Revenue Driver in Q3 2026 You know, Baidu's got one heck of a story this quarter. Despite some clouds hanging over them, they’ve managed to find a silver lining in their AI ventures. It’s like they’ve got this magic bullet with AI Cloud growth skyrocketing 94% year over year. That’s not just a rabbit outta the hat; it’s more like pulling a...

Continue Reading
NestWorks' C500: Shaking Up CNC at Formnext 2026

Updated Category News Views 120

NestWorks C500: A Game Changer for Makers Folks, gather 'round, because NestWorks is turning heads with their C500 desktop CNC machine. As it lands firmly on TIME’s Best Inventions of 2026 list, this ain't just another gadget adorning a workshop—all eyes are on it at Formnext 2026. From November 17–20, Frankfurt is the stage where NestWorks plans to showcase how...

Continue Reading
Exploring Why Dead Outlets Stay Dead: Expert Insights

Updated Category News Views 29

The Mystery of Non-Responsive Outlets Ever found an electrical outlet refusing to cooperate when you need it most? Well, I know the frustration all too well. You'd think if the breaker ain't blown, the outlet should work like a charm. But dive into the guts of the story, and you find a series of surprises waiting to trip us up. Common Culprits: Tripped GFCIs and Loose...

Continue Reading
Jones Soda Expands into Nutrition with UCAN Deal

Updated Category News Views 145

Well, Jones Soda Co. (CSE: JSDA) is stirring the pot with its recent move to acquire the UCAN functional nutrition assets. Popped the news on November 12, 2026, and it turns out they've shelled out a cool $700,000 in cash and taken on $500,000 in liabilities for the privilege. This isn't some casual shuffle of dollars and cents—this one's a strategic gambit aimed at...

Continue Reading

Top 5 Most Recently Viewed Articles

FTI Consulting Welcomes New Leaders to Enhance Transactions Team

Updated Category News Views 162

FTI Consulting Expands Expertise in Transactions Practice FTI Consulting, Inc. has recently announced the addition of two seasoned M&A professionals to its Transactions practice within the Corporate Finance & Restructuring segment. This strategic move aims to enhance their offerings and support clients in managing complex transactions. Introduction of M&A Experts The...

Continue Reading
BetaNXT Recognized as Leader in Wealth Management Innovation

Updated Category News Views 309

BetaNXT Earns Recognition as a Trendsetter in Wealth Management BetaNXT has captured attention in the financial technology landscape, particularly with its groundbreaking DataXChange platform. This innovative solution is designed to enhance modernization and innovation in wealth management, fostering business growth through a connected data ecosystem. Finalist in...

Continue Reading
OysterLink Sees Record Interest in Hospitality Job Searches

Updated Category News Views 124

Surging Demand for Restaurant and Hospitality Positions New analysis indicates that interest in restaurant and hospitality jobs has surged, reaching the highest level seen in five years. This summer's data from OysterLink's platform, combined with nationwide Google Trends, showcases a remarkable uptick in searches and applications, highlighting a strong rebound in the...

Continue Reading
Innovative Lithium Battery Solutions Enhanced by ITU and Huawei

Updated Category News Views 315

Joint Innovations in Lithium Battery Technology At the prestigious Global Digital Power Summit, a collaboration between the International Telecommunication Union (ITU) and Huawei brought significant attention to lithium battery applications for telecom sites. With industry leaders and experts congregating, the dialogue centered around technological advancements aimed at...

Continue Reading
Licel vTEE Continues to Lead in EMVCo TEE Success

Updated Category News Views 130

Licel vTEE Achieves EMVCo Approval Again The groundbreaking virtual trusted execution environment, Licel vTEE, stands out as the only SBMP TEE to receive evaluation and approval from EMVCo. This marks another milestone in the continued recognition of Licel's innovative technology. Unprecedented Recognition for Android Platform Licel's vTEE has received re-evaluation and...

Continue Reading